Pancreatic cancer has the worst survival rate of any cancers, with immunotherapies currently offering negligible treatment benefits for patients. To help identify new therapeutic approaches, researchers from the University of Oxford have been focusing on leukocyte infiltration as a prognostic marker of the disease. Their study and findings were outlined by Dr Shivan Sivakumar during a session…
Experts have identified two distinct immunological and cellular profiles in the lungs of Covid-19 patients which they believe could help define treatment pathways. From some of the earliest Covid-19 autopsies conducted in Europe, Swiss-based researchers have performed integrative digital pathology and transcriptomic analyses of lung tissues of 16 coronavirus patients who died from respiratory…
Researchers at Duke University and the University of California, Los Angeles, have developed a biomaterial that significantly reduces scar formation after wounding, leading to more effective skin healing. This new material, which quickly degrades once the wound has closed, demonstrates that activating an adaptive immune response can trigger regenerative wound healing, leaving behind stronger and…
‘Mini-lungs’ grown from tissue donated to Cambridge hospitals has provided a team of scientists from South Korea and the UK with important insights into how COVID-19 damages the lungs. Writing in the journal Cell Stem Cell, the researchers detail the mechanisms underlying SARS-CoV-2 infection and the early innate immune response in the lungs.
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research– from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research.
Our immune system can efficiently fend off viral diseases. Two types of immune cells play an important role in this process: The T-cells, which firstly can directly destroy virus-infected cells and secondly enable the formation of efficient, virus-neutralizing antibodies by B-cells. These two cell types also play a crucial role in the immune defense against SARS-CoV-2 infection. Whereas antibody…
As the COVID-19 pandemic continues to claim lives around the world, much research has focused on the immune system’s role in patients who become seriously ill. A popular theory has it that the immune system gets so revved up fighting the virus that, after several days, it produces a so-called cytokine storm that results in potentially fatal organ damage, particularly to the lungs.
The SARS CoV-2 virus which causes COVID-19 may have been named prematurely. As more has become known about the infection, the severe disease does not appear to be a respiratory syndrome at all. Patients who only have a respiratory illness tend not to have a severe condition, while patients who develop a severe condition tend to have non-respiratory conditions, primarily thrombotic or hyper-immune…
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and inhibition.
Although its name is relatively unspecific and indeed opaque, the Nonstructural Protein 1 (Nsp1) encoded by the coronavirus SARS-CoV-2, which is responsible for the current pandemic, has now been shown to have a devastating effect on host cells. Nsp1 is in fact one of the central weapons used by the virus to ensure its own replication and propagation in human hosts. Nsp1 was identified as a…
Cold Spring Harbor Laboratory (CSHL) Associate Professor Mikala Egeblad and her colleagues describe a newly understood way by which breast cancer cells sabotage a key player in the body’s immune system. That key player provides local immune surveillance by activating killer T-cells, but if it cannot mature and do its job, breast cancer cells can escape detection from the immune system,…
Which patient will develop a severe form of COVID-19? This is an essential question which must be answered in order to improve the individual management and the prognosis of these patients. In a publication in the journal Science, teams from the Assistance publique – Hôpitaux de Paris (AP-HP), Inserm, Université de Paris, Institut Pasteur and Institut Imagine describe a unique and unexpected…
Better outcomes, more favourable prognoses – oncologists and their lung cancer patients didn’t dare to dream about it. Finally, there might be hope. The so-called checkpoint inhibitors (immunotherapy drug) have been used successfully, albeit not for every patient. They are a double-edged sword, with risks as well as opportunities, as explained by Professor Cornelia Schäfer-Prokop.
It remains one of the key questions of the current corona pandemic: Why do people infected with SARS-CoV-2 experience varying degrees of COVID-19, the disease which it triggers? Researchers, led by Professor Mascha Binder from University Hospital Halle (Saale), have investigated more than 14 million receptor sequences of B and T cells, i.e. immune cells, obtained from blood samples of COVID-19…
Infections can trigger a particularly strong immune reaction of the body (termed sepsis). In such a sepsis the immune system reacts so strongly that not only the pathogens but also tissues and organs are damaged. In a study with mice, researchers from the Technische Universität Braunschweig were able to show that sepsis can have long-term effects on the brain and learning behaviour even after…
Infection with the novel coronavirus SARS-CoV-2 follows a highly variable course: some of those infected do not even notice it, while others become so seriously ill that their lives are placed at risk. Scientists from the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin and their colleagues from Leipzig and Heidelberg have now discovered that the immune system has a…
The first round of results from an immunological study of 149 people who have recovered from COVID-19 show that although the amount of antibodies they generated varies widely, most individuals had generated at least some that were intrinsically capable of neutralizing the SARS-CoV-2 virus. Antibodies vary widely in their efficacy. While many may latch on to the virus, only some are truly…
Leading immunologists in Japan are proposing a possible molecular mechanism that causes massive release of proinflammatory cytokines, or a cytokine storm, leading to the acute respiratory distress syndrome (ARDS) in COVID-19 patients. Their suggestions, published in the journal Immunity, are based on recent findings that explain how SARS-CoV-2 enters human cells.
